 "What is Diabetes?")
Diabetes
What is Diabetes?
Read More
Latest Updates on Diabetes
Generic semaglutide market shows signs of excess inventory bulge
Distributors grapple with rising semaglutide inventory amid slower liquidation
 "Generic semaglutide market shows signs of excess inventory bulge")
Dexcom's glucose monitor use benefits non-insulin diabetic patients: Study
Participants using the Dexcom G7 saw an average 1.6% reduction in their blood sugar levels at 26 weeks, a 0.9% greater reduction than those who used self-monitoring
 "Dexcom's glucose monitor use benefits non-insulin diabetic patients: Study")
Alkem launches semaglutide pre-filled syringes in India at ₹350
The company has received DCGI approval for multiple dosage strengths and aims to widen access to semaglutide treatment for diabetes and obesity
 "Alkem launches semaglutide pre-filled syringes in India at ₹350")
Best of BS Opinion: HDFC Bank must emphatically address all concerns
Hello and welcome to BS Opinion, a wrap of editorials and columns on today's Opinion page
 "Best of BS Opinion: HDFC Bank must emphatically address all concerns")
Improving health outcomes: Survey suggests the need for a holistic approach
NFHS-6 shows gains in child nutrition and healthcare access, but rising obesity and diabetes underscore the need for a more comprehensive public health strategy
 "Improving health outcomes: Survey suggests the need for a holistic approach")
Worsening side effects of life in fast lane: Obesity, diabetes up sharply
Lifestyle diseases on the rise, shows NFHS-6, though insurance coverage, vaccination rates, maternal care, child health indicators have improved
 "Worsening side effects of life in fast lane: Obesity, diabetes up sharply")
India's pharma market grows 10.3% in April on strong chronic performance
India's pharmaceutical market grew 10.3 per cent in April, led by strong demand for anti-diabetes, cardiac and respiratory therapies
 "India's pharma market grows 10.3% in April on strong chronic performance")
GLP-1 sees strong return dosage in China and Japan as India lags on value
Global drugmakers are prioritising China and Japan for GLP-1 investments due to stronger pricing power and adoption, while India remains a large but price-sensitive market with slower premium uptake
 "GLP-1 sees strong return dosage in China and Japan as India lags on value")
Alembic Pharma receives USFDA approval for generic dapagliflozin tablets
Dapagliflozin tablets are used to control blood sugar levels in people with type-2 diabetes
 "Alembic Pharma receives USFDA approval for generic dapagliflozin tablets")
Govt issues guidelines on GLP-1 drugs use, risks, and regulations
To prevent unauthorised sale, unsupervised use, and other malpractices, the Drug Controller of India has intensified its regulatory surveillance, warning that the drugs can lead to serious side effect
 "Govt issues guidelines on GLP-1 drugs use, risks, and regulations")
Aurobindo gains 3%, stock hits 52-week high; JM Financial sees more upside
In the past one month, Aurobindo has outperformed the market by surging 9 per cent, as compared to 8.5 per cent decline in the BSE Sensex.
 "Aurobindo gains 3%, stock hits 52-week high; JM Financial sees more upside")
10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt
Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations
 "10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt")
Semaglutide prices crash up to 90% as 15+ generics launch in two days
Off-patent GLP-1 therapy drives 70-90% price drop with generics flooding in
 "Semaglutide prices crash up to 90% as 15+ generics launch in two days")
Dr Reddy's enters semaglutide market, launches diabetes generic drug
Drugmaker expects to receive regulatory approval for weightloss sema generic in a few months
 "Dr Reddy's enters semaglutide market, launches diabetes generic drug")
Semaglutide generics may fuel rush for cosmetic weight loss, warn doctors
As semaglutide goes off patent, doctors warn of misuse by non-obese individuals amid rising demand driven by social media and lower-cost generics
 "Semaglutide generics may fuel rush for cosmetic weight loss, warn doctors")
Delhi HC seeks response from Centre, CDSCO over misuse of diabetes drugs
The matter has been posted for hearing on May 21
 "Delhi HC seeks response from Centre, CDSCO over misuse of diabetes drugs")
Study links fathers' nicotine use to altered metabolism in children
A new mouse study suggests nicotine exposure in fathers before conception may alter how their children process sugar and metabolism, potentially raising diabetes risk in the next generation
 "Study links fathers' nicotine use to altered metabolism in children")
GLP-1 drugs may fight addiction across every major substance: Study
Patients on GLP-1 drugs report losing cravings for addictions, ranging from opioids to gambling, prompting researchers to examine whether these diabetes and obesity medicines can curb addiction
Novo Nordisk, Abbott tie up to launch second Ozempic brand in India
Abbott will commercialise Extensior, a second semaglutide brand of Ozempic in India, as part of Novo Nordisk's strategy to expand access amid rising demand and looming patent expiry
 "Novo Nordisk, Abbott tie up to launch second Ozempic brand in India")
Green vs brown coconut water: Which one is actually healthier for you?
As coconuts mature from green to brown, their sugar levels, electrolyte balance and metabolic impact shift, and doctors explain which version suits your health needs better
 "Green vs brown coconut water: Which one is actually healthier for you?")